Cryoport Launches Self-Sustaining Cryogenic Freezer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy CYRX?
Source: PRnewswire
- Product Launch: Cryoport has unveiled the MVE Fusion®800 Series self-sustaining cryogenic freezer, eliminating the need for a continuous liquid nitrogen supply, which enhances reliability and safety in space-constrained environments, potentially setting a new industry standard for biological material storage.
- Space Efficiency: With a width of just 32 inches, the Fusion 800 can easily fit through standard doorways for installation, avoiding costly facility modifications typically required by traditional cryogenic systems, thereby reducing infrastructure burdens for customers and increasing market adoption.
- Wide Application Potential: This freezer is ideal for medical research facilities, clinical development, hospital pharmacies, and more, maintaining steady temperatures at or below -150°C, which meets stringent storage requirements for biological samples and life-saving therapies, likely encouraging more facilities to adopt true cryogenic storage.
- Industry Recognition: MVE's Fusion technology has received the ISBER Outstanding New Product Award, highlighting Cryoport's innovative capabilities in cryogenic storage, and the Fusion 800 is expected to become the new standard in research facilities and hospital pharmacies worldwide, further solidifying Cryoport's leadership in the life sciences supply chain.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CYRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CYRX
Wall Street analysts forecast CYRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.090
Low
11.00
Averages
11.00
High
11.00
Current: 8.090
Low
11.00
Averages
11.00
High
11.00
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
See More
Cryoport (CYRX) Q4 2025 Earnings Call Transcript
See More
CryoPort Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: CryoPort reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.06; however, revenue reached $45.5 million, reflecting a 9.6% year-over-year increase and beating market expectations by $2.58 million, indicating robust growth in the biopharmaceutical logistics sector.
- Annual Revenue Guidance: The company provided a revenue guidance for FY 2026 of $190 million to $194 million, projecting an 8% to 10% year-over-year growth, which reflects a positive outlook on future market demand and may attract more investor interest in its long-term growth potential.
- Market Reaction: Despite the EPS miss, the strong revenue performance could boost investor confidence in the short term, potentially driving the stock price up and improving the company's image in the capital markets.
- Industry Outlook: With the ongoing expansion of the biopharmaceutical industry, CryoPort's growth potential is significant, particularly in cold chain logistics and biological sample transportation, which is expected to further solidify its market position and drive future business development.
See More
Cryoport Exceeds Revenue Guidance in 2025 Financial Results
- Significant Revenue Growth: Cryoport reported full-year revenue of $176.2 million for 2025, exceeding guidance and reflecting strong demand in the cell and gene therapy market, particularly with commercial CGT support revenue increasing 29% year-over-year to $33.4 million, showcasing the company's leadership in a rapidly growing sector.
- Clinical Trial Support Innovation: As of 2025, Cryoport supported a record 760 global clinical trials, an increase of 59 from 2024, with approximately 70% being CGT trials, indicating the company's ongoing expansion in clinical research and robust market demand.
- Strategic Partnership Enhances Competitiveness: Cryoport formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, expected to provide substantial capital infusion and enhance the company's competitive profile in the EMEA and APAC regions, supporting future growth strategies.
- Optimistic Future Outlook: Cryoport anticipates full-year revenue guidance of $190 million to $194 million for 2026, reflecting confidence in future market opportunities while continuing to focus on improving operational efficiency and profitability.
See More
CryoPort to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
See More
Cryoport (CYRX) Q4 2025 Earnings Call Transcript
See More
CryoPort Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: CryoPort reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.06; however, revenue reached $45.5 million, reflecting a 9.6% year-over-year increase and beating market expectations by $2.58 million, indicating robust growth in the biopharmaceutical logistics sector.
- Annual Revenue Guidance: The company provided a revenue guidance for FY 2026 of $190 million to $194 million, projecting an 8% to 10% year-over-year growth, which reflects a positive outlook on future market demand and may attract more investor interest in its long-term growth potential.
- Market Reaction: Despite the EPS miss, the strong revenue performance could boost investor confidence in the short term, potentially driving the stock price up and improving the company's image in the capital markets.
- Industry Outlook: With the ongoing expansion of the biopharmaceutical industry, CryoPort's growth potential is significant, particularly in cold chain logistics and biological sample transportation, which is expected to further solidify its market position and drive future business development.
See More
Cryoport Exceeds Revenue Guidance in 2025 Financial Results
- Significant Revenue Growth: Cryoport reported full-year revenue of $176.2 million for 2025, exceeding guidance and reflecting strong demand in the cell and gene therapy market, particularly with commercial CGT support revenue increasing 29% year-over-year to $33.4 million, showcasing the company's leadership in a rapidly growing sector.
- Clinical Trial Support Innovation: As of 2025, Cryoport supported a record 760 global clinical trials, an increase of 59 from 2024, with approximately 70% being CGT trials, indicating the company's ongoing expansion in clinical research and robust market demand.
- Strategic Partnership Enhances Competitiveness: Cryoport formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, expected to provide substantial capital infusion and enhance the company's competitive profile in the EMEA and APAC regions, supporting future growth strategies.
- Optimistic Future Outlook: Cryoport anticipates full-year revenue guidance of $190 million to $194 million for 2026, reflecting confidence in future market opportunities while continuing to focus on improving operational efficiency and profitability.
See More
CryoPort to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
See More
